Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 <i>Diabetes Mellitus</i> Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and <i>De Novo</i> Evolution

Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 <i>Diabetes Mellitus</i> Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and <i>De Novo</i> Evolution

Dipeptidyl peptidase-IV (DPP-IV) rapidly breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Thus, the use of DPP-IV inhibitors to retard the degradation of endogenous GLP-1 is a possible mode of therapy correcting the defect in incre...

Full description

Bibliographic Details
Main Authors: Azizullo Musoev, Sodik Numonov, Zhuhong You, Hongwei Gao
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Molecules
Subjects:
DPP-IV
T2DM
inhibitors
pharmacophore models
docking
cross-docking
Online Access:https://www.mdpi.com/1420-3049/24/16/2870

Internet

https://www.mdpi.com/1420-3049/24/16/2870

Similar Items